We very much appreciate the endorsement of the International Uniform Response Criteria 1 expressed by Prince et al. 2 Their study documents the type of concerns based on which these new criteria were developed collaboratively by investigators from around the world, representing several major myeloma groups. Incorporation of the uniform response criteria in all future myeloma trials will eliminate the serious problem that Prince and co-workers document of markedly different response rates seen in a given trial depending on which of the many existing myeloma-specific response criteria were used to analyze the results.
The rigorous end point of stringent complete response (sCR) in addition to complete response (CR) and very good partial response (VGPR) in the new criteria are particularly important and useful to compare outcomes with novel therapy. We agree that higher levels of response can translate into longer time for progression and improved overall survival. Therefore, precise documentation of higher levels of response (i.e., depth of response) is especially important to allow early detection of potential longer-term benefit.
The new criteria do distinguish relapse from CR from progressive disease for the purposes of calculating time to progression (TTP) and progression free survival (PFS). Relapse from CR is not the end point used to calculate TTP or PFS; instead patients in CR will need to meet criteria for progressive disease for purposes of calculating these end points. There are three reasons for this change. First, relapse from CR is best used when disease free survival is the end point. Second, the test used to define relapse from CR (immunofixation) often fluctuates in a given patient from positive to negative, and is subject to interobserver variation. Third, this change eliminates the potential problem that can occur in future studies as higher CR rates are encountered of ''shorter TTP'' for patients in CR compared to patients who are not in CR, merely based on the inherent variability in the immunofixation results.
More detailed recommendations concerning frequency of disease assessment and other issues as well as protocol selection and entry criteria are ongoing initiatives of the International Myeloma Working Group. Standard induction chemotherapy for acute myeloid leukemia (AML), using cytarabine plus an anthracycline, results in complete remission (CR) in about 55% of patients aged 60 years and over. However, most older patients subsequently relapse, and less than 15% are long-term survivors. [1] [2] [3] Patients with poor-risk cytogenetic abnormalities, or secondary AML, have a particularly poor prognosis, with CR rates in the 30% range and virtually no long-term remissions. 2, 3 Many older patients are medically unfit for such aggressive therapy owing to co-morbid medical conditions, or do not wish to receive such therapy. For such patients, the prognosis is bleak; supportive care alone is associated with a median survival of 3-4 months. Relapsed patients also do poorly with low remission rates and short remission duration. 4 There is therefore a clear need for newer active agents in elderly AML patients, particularly those with poor-risk features. Temozolomide (TMZ) is an imidazotetrazine derivative of dacarbazine that functions as an alkylating agent and has high oral bioavailability. In a phase I study in relapsed/refractory AML, the maximum tolerated dose (MTD) was found to be 200 mg/m 2 p.o. daily for 7 days. 5 Of 19 patients treated, four achieved complete clearance of bone marrow blasts. Both induction and post-remission therapy (using 5 days cycles of TMZ) were well tolerated in this study.
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One identified mechanism of TMZ resistance is mediated by expression of O 6 -methylguanine-DNA methyltransferase (MGMT), a DNA repair enzyme. MGMT-expressing AML cell lines are less sensitive to TMZ; furthermore, transfection of MGMT into sensitive AML cell lines renders the cells resistant to TMZ. 6 Methylation of the MGMT gene promotor region turns off MGMT production, whereas an unmethylated MGMT promotor results in active synthesis of the enzyme. MGMT promotor methylation has been correlated with improved survival in patients with glioblastoma treated with TMZ. 7 Based on the activity of TMZ in the phase I trial, we conducted a phase II study using this agent in poor prognosis patients aged X60 years with AML, using the MTD determined in the phase I study. We also evaluated MGMT expression and correlated this with response to TMZ therapy in these patients.
Previously untreated patients were eligible if they had one of the following: adverse risk cytogenetics (complete or partial deletions of chromosome 5 or 7, three or more numerical or structural abnormalities, 11q23 or inv [3] abnormalities) or secondary AML (antecedent hematologic disorder or therapyrelated AML). Previously treated patients not achieving complete remission (CR), or relapsing within 1 year of CR, after receiving one course of induction chemotherapy were also eligible. Patients were required to have an ECOG performance status of 0-2, a serum creatinine o2 Â the upper limit of normal (ULN) and bilirubin o2 Â ULN and aspartate aminotransferase and alanine aminotransferase o5 Â ULN. Hydroxyurea was permitted up to 48 h before starting TMZ. Apart from this, no other systemic chemotherapy or investigative agents were permitted within 4 weeks of study entry or during the study period.
Induction therapy consisted of TMZ 200 mg/m 2 p.o. daily Â 7 days. Granisetron 1 mg p.o. was administered before each dose of TMZ as antiemetic prophylaxis. Most patients were treated on an outpatient basis, unless they required admission for febrile neutropenia or other complications. Blood counts were checked twice weekly until hematologic recovery, and prophylactic transfusions were given as required.
Patients achieving CR or CRp with induction then received up to 6 monthly post-remission cycles of TMZ, each cycle at a dose of 200 mg/m 2 p.o. daily Â 5 days. Patients achieving a partial response (PR) were eligible to receive a second identical induction cycle of TMZ; if CR/CRp was achieved, they then proceeded to post-remission therapy. Patients not achieving either CR, CRp or PR after one induction cycle, or CR/CRp after two cycles, were removed from the study. Patients with systemic relapse during post-remission therapy were also removed from study.
Response criteria were as follows: CR:o5% blasts in a normocellular bone marrow, absolute neutrophil count (ANC) 41.0 Â 10 9 /l and platelets 4100 Â 10 9 /l, with no extramedullary disease; CRp: All criteria for CR except platelets o100 Â 10 9 /l and platelet transfusion independence; PR: 5-15% marrow blasts with 450% decrease in blasts compared to baseline, ANC 41.0 Â 10 9 /l and platelets 450 Â 10 9 /l. All other patients were considered nonresponders (NR). All subjects signed an informed consent; the study was approved by the hospital Research Ethics Board. TMZ was provided by Schering Canada.
Leukemic blasts were collected from either peripheral blood or bone marrow before treatment, and assayed for MGMT using standard Western blot, using b-actin as a loading control. MGMT expression was quantitated by densitometry, and scored using the following criteria:
Comparisons of response rates and MGMT expression were performed using Fisher's exact test. Po0.05 values were considered significant using two-sided testing.
A total of 46 patients were entered in the study; the baseline data are summarized in Table 1 . As shown in Table 2 , there were five complete responses (three CR, two CRp) for an overall complete response rate of 11%; four of these achieved CR with one induction cycle. Three patients had partial responses to the first TMZ induction cycle; one of these achieved CRp with reinduction, whereas the remaining two did not respond further to reinduction. The overall response rate (ORR ¼ CR þ PR) was therefore 7/46, or 15%. The response rate among the previously untreated patients was higher (6/27, or 22%) than in the patients who had received a prior induction (1/19, or 5%); however, this difference was not statistically significant (P ¼ 0.21). There was no correlation between age, gender or baseline white blood cells and response to therapy.
As shown in Table 2 , two CR patients completed all six cycles of post-remission therapy, and remained in CR beyond 1 year, off therapy. A third patient (no. 1) was found to have leukemia cells in the cerebrospinal fluid (CSF) after two cycles of consolidation; a third TMZ cycle was started in conjunction with intrathecal cytarabine. Although the CSF cleared, the patient developed cerebellar ataxia after 10 intrathecal chemotherapy treatments, and was then taken off study. She has remained in continuous CRp for 28 months, despite receiving no further therapy. The remaining two patients relapsed during consolidation therapy.
Most patients were treated on an outpatient basis. The most common induction toxicities included febrile neutropenia (33% of inductions), nausea/vomiting (14%) and restlessness/agitation (12%). There were three early induction deaths: two died of neutropenic infections within 2 weeks of initiating therapy; a third died of idiopathic interstitial pneumonitis. All patients required prophylactic red cell and platelet transfusion support during induction therapy. For the complete responders, the median number of days to ANC 40.5 Â 10 9 /l was 39 (range 0-54) and to sustained platelets 420 Â 10 9 /l was 36 (range 14-63). Patients receiving post-remission therapy (20 cycles in total) required no transfusion support and there were no episodes of febrile neutropenia.
MGMT results were available on 28 patients (61%); these did not include the three early deaths. The remaining patient samples either had insufficient amount of protein for electrophoresis or did not have adequate b-actin controls and were therefore not evaluable. Of the 28 samples, 10 (36%) were negative for MGMT, 8 (29%) were weakly positive and the remaining 10 (36%) were strongly positive. As shown in Table 3 , the frequency of MGMT negativity was higher in previously Letters to the Editor untreated patients than in patients failing one induction (50 vs 10%, P ¼ 0.048).
The correlation between MGMT expression and clinical responses to TMZ therapy is shown in Table 4 . As shown, absent MGMT expression was significantly correlated with a higher likelihood of response to TMZ (P ¼ 0.003 comparing negative vs positive MGMT expression). The ORR in the MGMTnegative cases was 60 vs 6% for the MGMT-positive group. In the previously untreated patients, the ORR was 56% (5/9) in the MGMT-negative patients vs 11% (1/9) in the MGMT-positive patients. In the previously treated group, the one MGMTnegative sample was from the only patient who attained CR with TMZ.
One patient (no. 5 in Table 2 ), who achieved CR with TMZ and subsequently relapsed on consolidation therapy with TMZ, was re-assayed for MGMT expression at the time of relapse. This assay was performed simultaneously with blasts previously collected at diagnosis. As demonstrated in Figure 1 , MGMT expression at baseline was negative (MGMT:b actin ratio 0.079) and increased almost 10-fold at relapse (ratio 0.724).
The current study confirms the activity of TMZ in AML. As the ORR is low, the ability to identify subgroups with a higher likelihood of responding to therapy would be desirable. The study shows that patients whose blast cells demonstrate negative MGMT protein expression have a significantly higher likelihood of responding to TMZ therapy. The CR rate and ORR in MGMTnegative AML in this study (40 and 60%, respectively) are superior to CR rates in older patients with poor-risk cytogenetics or secondary AML treated with intensive therapy. 2, 3 Furthermore, this treatment was extremely well tolerated in this elderly population, and most patients were able to successfully complete therapy on an outpatient basis. Conversely, TMZ had no anti-leukemic activity in patients whose blast cells demonstrated strong MGMT expression (most such patients did not even demonstrate a reduction in circulating blasts), and very low activity in weak MGMT-expressing cases.
Previously published reports indicate that the frequency of MGMT DNA promoter methylation or low MGMT activity in AML is in the range of 10-25%. 8 However, in most reports, the status of the patients' disease or prior therapy was not taken into consideration. The current study suggests that the frequency of MGMT expression varies considerably between untreated and treated patients, with the former exhibiting a much higher frequency of negative MGMT expression (50 vs 10% for previously treated patients). This difference was only of borderline statistical significance; however, this may be due to the small numbers studied. The prior therapy in all cases had consisted of cytarabine and daunorubicin; no patient had received prior TMZ or other alkylating agent for their AML. This brings up the possibility that standard AML induction chemotherapy may be selecting for MGMT-expressing cells. As the current study was small and was not designed to address this question, this finding would require confirmation in a larger, carefully designed study.
The case in which MGMT expression was absent at diagnosis and high at relapse further supports the concept that low MGMT-expressing cells are preferentially killed by TMZ and that high MGMT-expressing cells are highly resistant to TMZ. One question is whether such resistance could be overcome with pharmacologic approaches. A number of inhibitors of MGMT have recently been described, including interferon, O 6 -benzylguanine and lomeguatrib, and some of these are in clinical trials. However, given the likelihood that MGMT plays an important role in effecting DNA repair in normal cells, inhibition of MGMT could potentially increase the toxicity to bone marrow and other non-malignant cells. Months from CR to relapse or last follow-up. 
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In summary, this study confirms that TMZ has activity in AML, and indicates that anti-leukemic responses correlate with MGMT expression, particularly in previously untreated patients. This correlation supports in vitro data indicating that MGMT is an important mediator of leukemia cell resistance to this agent. These findings require validation in a follow-up study, and such a study is currently in progress. If confirmed, this would establish TMZ as a reasonable front-line therapy option for older AML patients who are poor candidates for conventional induction chemotherapy, and whose blasts demonstrate very low or absent MGMT expression. Furthermore, MGMT-negative AML may potentially be a useful target for TMZ-containing combination regimens. In search of new markers for primitive hematopoietic cells, we have discovered that a recently described novel family of six putative transmembrane receptors, called slitrk1-slitrk6, are expressed on leukemic and lymphoma cells as well as hematopoietic stem cells. Slitrks belong to the leucine-rich repeat superfamily. They are single-pass transmembrane proteins, with homology to the slit family in the N-terminal extracellular domain and to the trk neurotrophin receptors in the C-terminal intracellular domain; hence assigned with the name slitrk. 1 Slitrks are highly conserved through evolution, with the human slitrks being 89-97% homologous to murine slitrks.
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2 Aruga and Mikoshiba 1 described the expression pattern of these genes in the developing brain and spinal cord, as well as their involvement in controlling neurite migration and axonal guidance. We described previously the differential expression of slitrk5 (referred to as KIAA0918) on CD34 þ leukemic cell lines. 3 These data led to the hypothesis that they were relevant for hematopoiesis and possibly leukemogenesis. Results from the present study revealed that of 13 leukemic cell lines all four acute lymphoblastic leukemia, five out of seven acute myeloid leukemia and all of two chronic myelogenous leukemia cell lines express one or more members of the slitrk family (Figure 1a) . Comparison of the two closely related cell lines KG1 and KG1a revealed a specific expression pattern for slitrk4: it is expressed only by the undifferentiated variant KG1a, but not by the parental KG1 cell line. Only two leukemic cell lines do not express any of the slitrks, namely the myeloid leukemic cell lines NB4 and HL60. Although no clear-cut expression pattern could be detected, there is a trend toward lymphoblastic leukemic cells expressing more slitrk1 and slitrk6, whereas myeloid leukemic cells express more slitrk4 and slitrk5. The lymphoma cell lines showed a distinct expression pattern; for example, two cell lines (Daudi and GA10) show no expression of any of the slitrks whereas three cell lines (BC1, BC3 and BCBL1) show expression of five out of six slitrks (Figure 1b) . Most notably, the latter cell lines are all primary effusion lymphomas (PEL), a distinct clinical entity of diffuse body cavity-located lymphomas with no single-tumor mass as well as a poorer prognosis in comparison to other lymphomas. 4, 5 To assess expression patterns of slitrks by primary cells, we studied the expression of slitrk genes on human mononuclear cells (MNC) isolated from peripheral blood, human umbilical vein endothelial cells (HUVEC), human fetal bone stroma (BS), human foreskin fibroblast (HFF) and human umbilical vein stroma cells (HUVSC), and human Miz-hES5 embryonic stem cells by reverse transcriptase-polymerase chain reaction (RT-PCR). All six members of the slitrk family were expressed by human embryonic stem cells (ESC) (Figure 1c) . To exclude the possibility of contamination by mouse embryonic fibroblast
